Emily Bodnar’s rating relies around the anticipation of significant milestones for Agenus in the approaching calendar year, specifically the probable submitting of the Biologics License Application (BLA) for his or her guide drug prospect, botensilimab (bot). Agenus has dosed around 900 individuals with bot throughout many strong tumors, showing